- ICH GCP
- EU Clinical Trials Registry
Latest Trials
EudraCT Number: 2022-003124-41 | Sponsor Protocol Number: 219510 | Start Date: 2023-03-27 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name: GlaxoSmithKline Biologicals SA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A non-randomized, open label, multi-country, cohort study to describe the safety of study participants who received RSVPreF3 maternal vaccination (any dose) or controls from previous RSV MAT studie... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Pregnancy related outcomes and events in maternal participants who were vaccinated against RSV or received control, and in their infants | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: FI (Ongoing) BE (Ongoing) FR (Ongoing) ES (Ongoing) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002389-33 | Sponsor Protocol Number: CNTO1959CRD3007 | Start Date: 2023-03-27 | |||||||||||
Sponsor Name: Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Guselkumab for the Treatment of Participants with Crohn’s Disease After Surgical Resection | |||||||||||||
Medical condition: Crohn’s Disease After Surgical Resection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Temporarily Halted) HU (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002792-11 | Sponsor Protocol Number: KAN0007 | Start Date: 2023-03-27 | |||||||||||
Sponsor Name: Kancera AB | |||||||||||||
Full Title: KANDOVA - A two-part Phase Ib/IIa study to evaluate the safety and tolerability of KAND567, in combination with carboplatin therapy, and to determine the Recommended Phase II Dose (RPIID) of KAND56... | |||||||||||||
Medical condition: Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: NO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003628-42 | Sponsor Protocol Number: NBK182/1/2022 | Start Date: 2023-03-24 | |||||||||||
Sponsor Name: Medical University of Gdańsk | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Levosimendan Therapy in low ejection fraction Takotsubo Syndrome (LevoTako Trial) | |||||||||||||
Medical condition: Takotsubo syndrome (TTS), also known as apical ballooning syndrome, Takotsubo cardiomyopathy, broken heart syndrome, and stress-induced cardiomyopathy, is a rare condition and accounts for 1–3% of ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002959-18 | Sponsor Protocol Number: PRN1008-017/ACT17125 | Start Date: 2023-03-23 | |||||||||||
Sponsor Name: Principia Biopharma Inc | |||||||||||||
Full Title: An open label, two-arm, Phase 2a study to evaluate the effect of rilzabrutinib (PRN1008/SAR444671) on safety and disease activity in patients with IgG4-related disease | |||||||||||||
Medical condition: IgG4-related disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004849-20 | Sponsor Protocol Number: 283PD201 | Start Date: 2023-03-22 | |||||||||||
Sponsor Name: Biogen Idec Research Limited | |||||||||||||
Full Title: A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants with Parkinson’s Disease | |||||||||||||
Medical condition: Parkinson's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) ES (Ongoing) FR (Ongoing) NL (Ongoing) AT (Ongoing) PL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2023-000150-20 | Sponsor Protocol Number: 1 | Start Date: 2023-03-22 | ||||||
Sponsor Name: Bispebjerg-Frederiksberg Hospital | ||||||||
Full Title: The effect of exercise on pharmacodynamics and pharmacokinetics of a single dose of unfractionated heparin: A randomized, controlled, cross-over study | ||||||||
Medical condition: Unfractionated heparin is used for the prevention and treatment of deep vein thrombosis and complications hereof | ||||||||
|
||||||||
Population Age: Adults | Gender: Male | |||||||
Trial protocol: DK (Completed) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001796-14 | Sponsor Protocol Number: CYTB323G12101 | Start Date: 2023-03-20 | |||||||||||
Sponsor Name: Novartis Pharma AG | |||||||||||||
Full Title: An open-label, multi-center, phase 1/2 study to assess safety, efficacy and cellular kinetics of YTB323 in participants with severe, refractory systemic lupus erythematosus. | |||||||||||||
Medical condition: Systemic Lupus Erythematosus Lupus Nephritis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-004079-17 | Sponsor Protocol Number: COMBATARF | Start Date: 2023-03-20 | |||||||||||
Sponsor Name: Rigshospitalet | |||||||||||||
Full Title: Efficacy and safety of 72-hour infusion of Prostacyclin (1 ng/kg/min) in mechanically ventilated patients with infectious pulmonary endotheliopathy – a multicentre randomized, placebo-controlled, b... | |||||||||||||
Medical condition: Infectious pulmonary endotheliopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002966-34 | Sponsor Protocol Number: TAK-861-2002 | Start Date: 2023-03-20 | |||||||||||
Sponsor Name: Takeda Development Center Americas, Inc. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-861 for the Treatment of Narcolepsy Without Cataplexy (Narcolepsy Type 2) | |||||||||||||
Medical condition: Narcolepsy without Cataplexy (Type 2) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) SE (Ongoing) FR (Ongoing) IT (Ongoing) ES (Ongoing) FI (Completed) | |||||||||||||
Trial results: (No results available) |